Skip to main content
Log in

Sesquiterpene from Artemisia argyi seed extracts: A new anti-acute peritonitis agent that suppresses the MAPK pathway and promotes autophagy

  • Original Article
  • Published:
Inflammopharmacology Aims and scope Submit manuscript

Abstract

To find novel anti-inflammatory drugs, we screened anti-inflammatory compounds from 18 different types of Artemisia argyi seed extracts. The in vitro and in vivo anti-inflammatory activities of the screened compounds and their mechanisms were characterized. We first detected the cytotoxic effect of the compounds on RAW264.7 cells and the inhibitory effect on LPS-induced NO release. It was found that sesquiterpenoids CA-2 and CA-4 had low cytotoxic and strong NO inhibitory activity with an IC50 of 4.22 ± 0.61 μM and 2.98 ± 0.23 μM for NO inhibition, respectively. Therefore, compound CA-4 was studied in depth. We found that compound CA-4 inhibited LPS-induced pro-inflammatory factor production and M1 macrophage differentiation in RAW264.7 cells. Additionally, CA-4 inhibited the expression of p-ERK1/2, p-JNK, iNOS, and COX-2 by blocking the MAPK signaling pathway. CA-4 also promoted the expression of autophagy-related proteins such as LC3 II and Beclin-1 by inhibiting activation of the PI3K/AKT/mTOR signaling pathway, and promoted the generation of autophagosomes. Finally, CA-4 significantly inhibited the degree of inflammation in mice with acute peritonitis, showing good anti-inflammatory activity in vivo. Consequently, compound CA-4 may be a promising drug for the treatment of acute inflammatory diseases and provide new ideas for the synthesis of novel anti-inflammatory compounds.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

Data availability

All data that support the findings of this study are available from the corresponding author upon reasonable request.

Abbreviations

AKT:

Protein kinase B

COX-2:

Cyclooxygenase 2

DEX:

Dexamethasone

ERK1/2:

Extracellular regulated protein kinases 1/2

iNOS:

Inducible nitric oxide synthase

JNK:

C-Jun N-terminal kinase

LPS:

Lipopolysaccharide

MAPK:

Mitogen-activated protein kinase

MCP-1:

Monocyte chemoattractant protein-1

mTOR:

Mammalian target of rapamycin

NSAIDs:

Nonsteroidal anti-inflammatory drugs

PI3K:

Phosphatidylinositol-3-kinase

SRB:

Sulfonyl rhodamine

TEM:

Transmission electron microscopy

References

Download references

Acknowledgements

Thanks to the Key Laboratory of Advanced Pharmaceutical Preparation Technology, Ministry of Education; School of Pharmaceutical Sciences, Zhengzhou University; and State Key Laboratory of Esophageal Cancer Prevention & Treatment; School of Pharmaceutical Sciences, Zhengzhou University for providing the experimental platform.

Funding

This work was supported by the Joint Fund of Provincial Science and Technology Research and Development Plan of Henan Province (Advantageous Discipline Cultivation) (Project No. 222301420057), The Open Project of Henan International Joint Laboratory of Prevention and Treatment of Pediatric Diseases, (Project No. EKB202202), and The Open Project of Henan Neurodevelopment Engineering Research Center for Children (Project No. SG202201).

Author information

Authors and Affiliations

Authors

Contributions

YL: conceptualization, validation, and writing—original draft. YW: methodology, investigation, data curation, and writing—original draft. TL: methodology, data curation, and writing—original draft. ZL: methodology, TG: methodology. GX: conceptualization. YD: conceptualization and funding acquisition. YY: conceptualization, funding acquisition, supervision, and writing—review & editing.

Corresponding authors

Correspondence to Guimin Xue, Yongtao Duan or Yongfang Yao.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest regarding the publication of this review article.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, Y., Wang, Y., Li, T. et al. Sesquiterpene from Artemisia argyi seed extracts: A new anti-acute peritonitis agent that suppresses the MAPK pathway and promotes autophagy. Inflammopharmacol 32, 447–460 (2024). https://doi.org/10.1007/s10787-023-01297-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10787-023-01297-8

Keywords

Navigation